The link between type III collagen deposition (PRO-C3) and resistance to ICIs is supported by a study of ECM gene dysregulation, in which a set of transforming growth factor-beta-(TGF-β)-driven ECM genes, including COL3A, predict ICI failure independent of tumor type [9]. Here, MMRN1 is linked to neoplasm.